Replies to post #120712 on Biotech Values

[investorgold2002]

page 3 non-infringement is confusing??

Since proving inequitable conduct is going to be pretty tough(see my other message), I am looking at their chance on non-infringement


http://208.78.96.220/2-10-10_Sandoz_reply_re_molecular_weight.pdf

why are they saying the proposed generic's avg mol weight or peak mol weight does not conform to within claimed ranges of branded drug copaxone ?

If so, how will this product be considered equivalent by FDA ????

somebody???